Abstract
Anaplastic thyroid carcinoma (ATC) is a rare cancer accounting for 40% of thyroid cancer-specific deaths. Median overall survival is 6 months. In the last 5 years, improved insights into molecular pathways led to the approval of BRAF/MEK inhibitors (B/Mi) in BRAFV600E-mutant ATC in the U.S.A. Nevertheless, many clinicians face challenges in prescribing new treatments, included immunotherapy (IO). The extent of this phenomenon is unknown in Europe, where no new treatment for ATC has been approved yet.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
